

Supplementary Data 1: Refractive & visual acuity outcome of stage 1 + preoperative refractive & visual acuity data
Stage 1: grouped by ORA / MRC // group A: ORA / MRC = 1 or less (= low ORA) / group B: ORA / MRC = 1.1 and more (= high ORA)

Table 1: Stage 1

Variable	Low ORA (Not Matched)								High ORA (Not Matched)								P-Value
	N	Min	Max	Mean	SD	Median	Q25	Q75	N	Min	Max	Mean	SD	Median	Q25	Q75	
Preoperative																	
K Mean	609	39.50	48.10	43.90	1.46	43.90	42.90	44.90	171	39.10	49.30	43.80	1.57	43.70	42.70	44.85	0.439*
K Cyl	609	-4.10	-0.10	-1.44	0.74	-1.30	-1.80	-0.90	171	-3.60	0.00	-1.10	0.68	-1.00	-1.60	-0.55	<0.001†
Sphere	609	-8.00	-0.25	-3.47	2.00	-3.25	-5.00	-1.75	171	-8.00	-0.25	-3.45	1.86	-3.25	-4.62	-2.00	0.990†
Cylinder	609	-4.00	-0.75	-1.43	0.70	-1.25	-1.75	-1.00	171	-1.75	-0.75	-0.88	0.21	-0.75	-1.00	-0.75	<0.001†
SE	609	-9.12	-0.75	-4.19	1.97	-4.00	-5.62	-2.62	171	-8.38	-0.62	-3.89	1.86	-3.75	-5.00	-2.38	0.100†
UDVA	607	0.00	0.80	0.10	0.14	0.05	0.01	0.10	169	0.00	0.78	0.11	0.16	0.05	0.01	0.10	0.987†
CDVA	609	0.80	1.53	1.04	0.12	1.00	0.96	1.15	171	0.80	1.39	1.03	0.12	1.00	0.96	1.15	0.621†
ORA	609	0.03	1.91	0.63	0.34	0.58	0.38	0.82	171	0.75	2.00	1.18	0.31	1.12	0.95	1.33	<0.001†
ORA MRC	609	0.03	1.00	0.48	0.25	0.45	0.28	0.67	171	1.00	2.60	1.35	0.33	1.26	1.09	1.55	<0.001†
Postoperative																	
K Mean	609	34.40	44.90	40.38	1.99	40.50	39.10	41.90	171	36.10	45.60	40.61	1.96	40.70	39.50	41.80	0.259†
K Cyl	609	-3.50	0.00	-0.82	0.46	-0.70	-1.10	-0.50	171	-6.10	0.00	-1.18	0.61	-1.10	-1.40	-0.90	<0.001†
Sphere	609	-1.50	2.25	0.25	0.49	0.25	0.00	0.50	171	-1.00	2.25	0.20	0.47	0.25	0.00	0.50	0.226†
Cylinder	609	-2.00	0.00	-0.39	0.36	-0.25	-0.50	0.00	171	-1.75	0.00	-0.41	0.36	-0.25	-0.50	-0.25	0.483†
SE	609	-1.75	1.62	0.05	0.43	0.00	-0.25	0.25	171	-1.12	1.62	0.00	0.41	0.00	-0.25	0.25	0.057†
UDVA	609	0.00	1.60	1.01	0.20	1.00	0.92	1.15	171	0.00	1.53	1.01	0.20	1.00	0.90	1.15	0.752†
CDVA	609	0.00	1.60	1.08	0.16	1.10	1.00	1.20	171	0.00	1.60	1.07	0.19	1.00	1.00	1.20	0.835†
ORA	609	0.00	2.50	0.70	0.38	0.66	0.42	0.90	171	0.05	5.94	0.93	0.56	0.90	0.61	1.12	<0.001†
EI	609	0.00	1.40	0.98	0.18	1.00	0.90	1.07	171	0.00	1.53	0.98	0.19	1.00	0.89	1.09	0.876†
SI	609	0.00	1.50	1.05	0.15	1.02	1.00	1.12	171	0.00	1.60	1.04	0.17	1.02	1.00	1.11	0.796†

* Independent T-Test.

† Mann-Whitney Test.

Supplementary Data 2: Refractive & visual acuity outcome of stage 2 + preoperative refractive & visual acuity data
Stage 2: grouped by ORA / MRC, matched for MRC / group A: ORA / MRC = 1 or less (= low ORA) / group B: ORA / MRC = 1.1 and more (= high ORA)

Table 3: Stage 2

Variable	Low ORA (Matched)								High ORA (Matched)								P-Value
	N	Min	Max	Mean	SD	Median	Q25	Q75	N	Min	Max	Mean	SD	Median	Q25	Q75	
Preoperative																	
K Mean	138	39.50	47.40	43.71	1.56	43.70	42.62	44.80	138	39.10	49.30	43.80	1.58	43.55	42.70	44.70	0.988 [†]
K Cyl	138	-2.10	-0.20	-1.06	0.39	-1.10	-1.30	-0.80	138	-3.60	0.00	-1.10	0.69	-1.00	-1.67	-0.60	0.954 [†]
Sphere	138	-8.00	-0.25	-3.53	1.90	-3.25	-4.75	-2.00	138	-8.00	-0.25	-3.53	1.90	-3.25	-4.75	-2.00	1.000 [†]
Cylinder	138	-1.75	-0.75	-0.89	0.19	-0.75	-1.00	-0.75	138	-1.75	-0.75	-0.89	0.19	-0.75	-1.00	-0.75	1.000 [†]
SE	138	-8.38	-0.75	-3.97	1.89	-3.75	-5.25	-2.41	138	-8.38	-0.75	-3.97	1.89	-3.75	-5.25	-2.41	1.000 [†]
UDVA	138	0.00	0.70	0.10	0.12	0.05	0.01	0.16	136	0.00	0.78	0.10	0.15	0.05	0.01	0.10	0.364 [†]
CDVA	138	0.80	1.46	1.08	0.13	1.05	1.00	1.20	138	0.80	1.32	1.03	0.12	1.00	0.96	1.10	0.002 [†]
ORA	138	0.03	1.02	0.49	0.23	0.49	0.32	0.65	138	0.75	2.00	1.17	0.30	1.12	0.98	1.30	<0.001 [†]
ORA MRC	138	0.03	0.99	0.56	0.25	0.57	0.34	0.79	138	1.00	2.60	1.34	0.33	1.24	1.07	1.55	<0.001 [†]
Postoperative																	
K Mean	138	34.40	44.60	40.34	2.16	40.60	38.70	42.00	138	36.10	45.60	40.51	1.97	40.60	39.39	41.60	0.875 [†]
K Cyl	138	-1.60	-0.10	-0.69	0.33	-0.70	-0.90	-0.40	138	-6.10	0.00	-1.17	0.63	-1.10	-1.40	-0.90	<0.001 [†]
Sphere	138	-0.50	1.50	0.19	0.43	0.25	0.00	0.50	138	-1.00	2.25	0.22	0.49	0.25	0.00	0.50	0.611 [†]
Cylinder	138	-1.25	0.00	-0.34	0.30	-0.25	-0.50	0.00	138	-1.50	0.00	-0.41	0.35	-0.25	-0.50	-0.25	0.121 [†]
SE	138	-1.12	1.38	0.02	0.40	0.00	-0.25	0.25	138	-1.12	1.62	0.02	0.43	0.00	-0.25	0.25	0.750 [†]
UDVA	138	0.00	1.60	1.04	0.20	1.05	0.96	1.15	138	0.00	1.53	1.00	0.21	1.00	0.90	1.15	0.020 [†]
CDVA	138	0.00	1.60	1.11	0.19	1.10	1.00	1.20	138	0.00	1.60	1.06	0.20	1.00	0.98	1.20	0.009 [†]
ORA	138	0.06	1.82	0.62	0.31	0.60	0.40	0.80	138	0.05	5.94	0.93	0.59	0.89	0.63	1.20	<0.001 [†]
EI	138	0.00	1.33	0.97	0.18	1.00	0.90	1.05	138	0.00	1.53	0.97	0.19	1.00	0.88	1.09	0.845 [†]
SI	138	0.00	1.39	1.04	0.17	1.00	1.00	1.11	138	0.00	1.60	1.03	0.18	1.02	1.00	1.11	0.941 [†]

* Independent T-Test.

† Mann-Whitney Test.

Supplementary Data 3: Refractive & visual acuity outcome of stage 3 + preoperative refractive & visual acuity data
Stage 3: Grouped by ORA magnitude, matched for MRC // group A: ORA = 0.49 and less (= low ORA) /
group B: ORA = 0.50 to 1.24 (= medium ORA) / group C: ORA = 1.25 and more (= high ORA)

Table 5: Stage 3 (Matched)

	Group	N	Min	Max	Mean	SD	Median	Q25	Q75
Preoperative									
K Mean P-Value=0.624	Low	38	40.20	46.50	43.70	1.68	43.90	42.50	44.72
	Moderate	38	39.50	47.90	43.65	1.63	43.40	42.60	44.65
	High	38	40.70	49.30	44.02	1.67	43.90	42.80	44.92
K Cyl P-Value=0.254	Low	38	-2.20	-0.50	-1.14	0.37	-1.20	-1.37	-0.90
	Moderate	38	-3.00	-0.40	-1.37	0.57	-1.40	-1.70	-1.00
	High	38	-3.60	-0.40	-1.33	0.84	-1.00	-1.98	-0.62
Sphere P-Value=1.000	Low	38	-8.00	-0.50	-3.24	1.92	-3.12	-4.00	-1.50
	Moderate	38	-8.00	-0.50	-3.24	1.92	-3.12	-4.00	-1.50
	High	38	-8.00	-0.50	-3.24	1.92	-3.12	-4.00	-1.50
Cylinder P-Value=1.000	Low	38	-2.25	-0.75	-1.05	0.36	-1.00	-1.19	-0.75
	Moderate	38	-2.25	-0.75	-1.05	0.36	-1.00	-1.19	-0.75
	High	38	-2.25	-0.75	-1.05	0.36	-1.00	-1.19	-0.75
SE P-Value=1.000	Low	38	-8.38	-1.25	-3.77	1.89	-3.56	-4.78	-2.12
	Moderate	38	-8.38	-1.25	-3.77	1.89	-3.56	-4.78	-2.12
	High	38	-8.38	-1.25	-3.77	1.89	-3.56	-4.78	-2.12
UDVA P-Value=0.843	Low	38	0.01	0.54	0.11	0.13	0.05	0.01	0.14
	Moderate	37	0.00	0.54	0.10	0.12	0.05	0.01	0.10
	High	38	0.00	0.40	0.09	0.11	0.05	0.01	0.10
CDVA P-Value=0.714	Low	38	0.80	1.20	1.03	0.10	1.00	0.98	1.10
	Moderate	38	0.90	1.25	1.06	0.11	1.00	0.98	1.15
	High	38	0.86	1.32	1.05	0.12	1.00	0.96	1.15
ORA P-Value<0.001	Low	38	0.07	0.49	0.30	0.12	0.32	0.21	0.40
	Moderate	38	0.50	1.24	0.84	0.21	0.84	0.67	1.02
	High	38	1.25	2.00	1.49	0.21	1.45	1.31	1.61
ORA MRC P-Value<0.001	Low	38	0.08	0.66	0.31	0.15	0.29	0.21	0.40
	Moderate	38	0.30	1.65	0.88	0.35	0.81	0.61	1.13
	High	38	0.61	2.60	1.54	0.43	1.56	1.29	1.80
Postoperative									
K Mean P-Value=0.603	Low	38	36.00	44.00	40.64	2.25	40.95	39.02	42.42
	Moderate	38	36.80	44.70	40.44	2.08	40.65	39.05	42.08
	High	38	36.10	45.60	40.95	2.10	40.90	39.90	42.08
K Cyl P-Value<0.001	Low	38	-1.30	0.00	-0.57	0.30	-0.60	-0.70	-0.40
	Moderate	38	-1.80	-0.20	-0.91	0.42	-0.90	-1.25	-0.50
	High	38	-6.10	-0.40	-1.48	0.91	-1.40	-1.70	-1.00
Sphere P-Value=0.309	Low	38	-0.50	1.50	0.12	0.41	0.12	-0.19	0.25
	Moderate	38	-1.00	2.25	0.20	0.55	0.00	0.00	0.44
	High	38	-0.75	1.25	0.29	0.51	0.25	0.00	0.50
Cylinder P-Value=0.002	Low	38	-1.00	0.00	-0.24	0.28	-0.25	-0.25	0.00
	Moderate	38	-1.25	0.00	-0.31	0.36	-0.25	-0.50	0.00
	High	38	-1.25	0.00	-0.50	0.35	-0.50	-0.75	-0.25
SE P-Value=0.934	Low	38	-0.62	1.00	0.01	0.36	0.00	-0.25	0.25
	Moderate	38	-1.12	1.62	0.04	0.45	0.00	-0.12	0.25
	High	38	-0.75	1.00	0.04	0.43	-0.06	-0.25	0.22
UDVA P-Value=0.948	Low	38	0.00	1.32	1.01	0.22	1.00	0.96	1.15
	Moderate	38	0.30	1.46	1.01	0.20	1.00	0.96	1.15
	High	38	0.00	1.32	1.02	0.24	1.02	0.94	1.15
CDVA P-Value=0.353	Low	38	0.88	1.32	1.08	0.11	1.05	1.00	1.20
	Moderate	38	0.70	1.32	1.09	0.14	1.05	1.00	1.25
	High	38	0.00	1.46	1.10	0.23	1.15	1.00	1.25
ORA P-Value<0.001	Low	38	0.00	0.98	0.54	0.27	0.57	0.36	0.80
	Moderate	38	0.16	1.57	0.74	0.34	0.71	0.50	0.98
	High	38	0.15	5.94	1.13	0.92	0.96	0.69	1.28
EI P-Value=0.700	Low	38	0.00	1.30	0.99	0.22	1.00	0.91	1.09
	Moderate	38	0.30	1.17	0.96	0.16	1.00	0.92	1.04
	High	38	0.00	1.38	0.99	0.23	0.98	0.90	1.12
SI P-Value=0.270	Low	38	0.83	1.33	1.06	0.11	1.01	1.00	1.10
	Moderate	38	0.70	1.32	1.03	0.09	1.02	1.00	1.09
	High	38	0.00	1.42	1.06	0.21	1.09	1.00	1.15

Supplementary Data 4: Refractive & visual acuity outcome of stage 4 + preoperative refractive & visual acuity data

Stage 4: Grouped by ORA magnitude, matched for MRC & then subdivided by CA magnitude // group A: CA <0,75D (low CA) / group B: CA ≥ 0,75D

Table 7: Stage 4

Variable	High ORA Low CA								High ORA High CA								P-Value
	N	Min	Max	Mean	SD	Median	Q25	Q75	N	Min	Max	Mean	SD	Median	Q25	Q75	
Preoperative																	
K Mean	15	40.70	44.70	43.30	1.05	43.30	42.75	44.10	23	41.80	49.30	44.49	1.85	44.40	42.90	45.90	0.016*
K Cyl	15	-0.70	-0.40	-0.59	0.11	-0.60	-0.70	-0.50	23	-3.60	-0.80	-1.82	0.74	-1.90	-2.25	-1.25	<0.001†
Sphere	15	-7.25	-1.00	-2.63	1.79	-1.75	-3.25	-1.38	23	-8.00	-0.50	-3.64	1.93	-3.75	-4.88	-2.00	0.068†
Cylinder	15	-1.75	-0.75	-1.03	0.28	-1.00	-1.00	-0.88	23	-2.25	-0.75	-1.07	0.41	-1.00	-1.38	-0.75	0.659†
SE	15	-8.00	-1.38	-3.15	1.83	-2.25	-3.75	-2.00	23	-8.38	-1.25	-4.17	1.86	-4.25	-5.31	-2.56	0.056†
UDVA	15	0.01	0.34	0.12	0.10	0.10	0.04	0.20	23	0.00	0.40	0.08	0.11	0.03	0.01	0.10	0.080†
CDVA	15	0.86	1.32	1.11	0.13	1.10	1.00	1.17	23	0.88	1.20	1.00	0.10	0.98	0.95	1.08	0.014*
ORA	15	1.26	1.81	1.46	0.17	1.45	1.29	1.56	23	1.25	2.00	1.52	0.23	1.45	1.35	1.67	0.575†
ORA MRC	15	0.74	1.93	1.48	0.28	1.53	1.42	1.65	23	0.61	2.60	1.59	0.51	1.68	1.22	1.91	0.388*
Postoperative																	
K Mean	15	36.10	43.40	40.65	1.95	41.20	40.15	41.70	23	37.00	45.60	41.14	2.21	40.50	40.00	42.30	0.481*
K Cyl	15	-1.80	-0.80	-1.25	0.34	-1.20	-1.55	-0.95	23	-6.10	-0.40	-1.63	1.13	-1.40	-1.80	-1.00	0.219†
Sphere	15	-0.50	1.25	0.27	0.48	0.25	0.00	0.50	23	-0.75	1.25	0.30	0.54	0.25	-0.12	0.50	0.823*
Cylinder	15	-1.25	0.00	-0.50	0.35	-0.50	-0.75	-0.25	23	-1.25	0.00	-0.50	0.36	-0.50	-0.75	-0.25	1.000*
SE	15	-0.50	0.75	0.02	0.37	0.00	-0.12	0.12	23	-0.75	1.00	0.05	0.48	-0.12	-0.25	0.25	0.787*
UDVA	15	0.84	1.32	1.12	0.17	1.15	0.95	1.25	23	0.00	1.32	0.96	0.26	0.98	0.92	1.10	0.068†
CDVA	15	1.00	1.32	1.19	0.10	1.25	1.15	1.25	23	0.00	1.46	1.04	0.27	1.00	0.99	1.20	0.009†
ORA	15	0.15	1.55	0.90	0.34	0.95	0.68	1.03	23	0.27	5.94	1.27	1.14	1.04	0.69	1.48	0.391†
EI	15	0.76	1.26	1.02	0.17	0.96	0.87	1.17	23	0.00	1.38	0.97	0.27	1.00	0.91	1.09	0.858†
SI	15	0.91	1.25	1.08	0.11	1.09	0.99	1.17	23	0.00	1.42	1.04	0.26	1.08	1.00	1.13	0.643†

* Independent T-Test.

† Mann-Whitney Test.

Supplementary data 5: Preoperative side effects of Stage 1

Stage 1: grouped by ORA / MRC // **group A**: ORA / MRC = 1 or less (= low ORA) / **group B**: ORA / MRC = 1.1 and more (= high ORA)

	N	Min	Max	Mean	SD	Median	Q25	Q75	P-Value
Starburst**									
Group A	180	1	5	1,05	0,43	1	1	1,00	0,531
Group B	108	1	4	1,08	0,50	1	1	1,00	
Glare**									
Group A	180	1	7	1,46	1,16	1	1	2,00	0,680
Group B	108	1	5	1,43	1,01	1	1	1,00	
Halo**									
Group A	180	1	3	1,03	0,26	1	1	1,00	0,130
Group B	108	1	4	1,14	0,63	1	1	1,00	
Double vision & ghost images**									
Group A	180	1	3	1,02	0,21	1	1	1,00	0,144
Group B	108	1	2	1,04	0,19	1	1	1,00	
**Scale of symptoms: low symptoms (1) to strong symptoms (7)									
***Scale of satisfaction: very satisfied (1) to very unsatisfied (5)									

Supplementary data 6: Preoperative side effects of Stage 2

Stage 2: grouped by ORA / MRC, matched for MRC / **group A:** ORA / MRC = 1 or less (= low ORA) / **group B:** ORA / MRC = 1.1 and more (= high ORA)

	N	Min	Max	Mean	SD	Median	Q25	Q75	P-Value
Starburst**									
Group A	38	1	1	1,00	0,00	1	1	1,00	NaN
Group B	36	1	1	1,00	0,00	1	1	1,00	
Glare**									
Group A	38	1	5	1,32	0,96	1	1	1,00	1,000
Group B	36	1	4	1,25	0,77	1	1	1,00	
Halo**									
Group A	38	1	3	1,05	0,32	1	1	1,00	0,969
Group B	36	1	4	1,08	0,50	1	1	1,00	
Double vision & ghost images**									
Group A	38	1	1	1,00	0,00	1	1	1,00	0,317
Group B	36	1	2	1,03	0,17	1	1	1,00	

**Scale of symptoms: low symptoms (1) to strong symptoms (7)
***Scale of satisfaction: very satisfied (1) to very unsatisfied (5)

Supplementary Data 7: Preoperative side effects of Stage 3

Stage 3: Grouped by ORA magnitude, matched for MRC // **group A:** ORA = 0.49 and less (= low ORA) / **group B:** ORA = 0.50 to 1.24 (= medium ORA) / **group C:** ORA = 1.25 and more (= high ORA)

	N	Min	Max	Mean	SD	Median	Q25	Q75	P-Value
Starburst**									
Group A	12	1	1	1,00	0,00	1	1	1,00	0,454
Group C	18	1	4	1,17	0,71	1	1	1,00	
Glare**									
Group A	12	1	5	1,83	1,40	1	1	1,00	0,980
Group C	18	1	4	1,89	1,37	1	1	3,50	
Halo**									
Group A	12	1	1	1,00	0,00	1	1	1,00	0,454
Group C	18	1	4	1,17	0,71	1	1	1,00	
Double vision & ghost images**									
Group A	12	1	1	1,00	0,00	1	1	1,00	0,454
Group C	18	1	2	1,06	0,24	1	1	1,00	

**Scale of symptoms: low symptoms (1) to strong symptoms (7)

***Scale of satisfaction: very satisfied (1) to very unsatisfied (5)

Supplementary data 8: Preoperative side effects of Stage 4

Stage 4: Grouped by ORA magnitude, matched for MRC & then subdivided by CA magnitude

// **group A:** CA < 0,75D (low CA) / **group B:** CA ≥ 0,75D

	N	Min	Max	Mean	SD	Median	Q25	Q75	P-Value
Starburst**									
Group A	8	1	1	1,00	0,00	1	1	1,00	0,434
Group B	10	1	4	1,30	0,95	1	1	1,00	
Glare**									
Group A	8	1	2	1,12	0,35	1	1	2,50	0,068
Group B	10	1	4	2,50	1,58	2,5	1	4,00	
Halo**									
Group A	8	1	1	1,00	0,00	1	1	1,00	0,434
Group B	10	1	4	1,30	0,95	1	1	1,00	
Double vision & ghost images**									
Group A	8	1	1	1,00	0,00	1	1	1,00	0,434
Group B	10	1	2	1,10	0,32	1	1	1,00	

**Scale of symptoms: low symptoms (1) to strong symptoms (7)
***Scale of satisfaction: very satisfied (1) to very unsatisfied (5)
CA = corneal astigmatism

Supplementary data 9: Postoperative side effects of Stage 3

Stage 3: Grouped by ORA magnitude, matched for MRC // **group A:** ORA = 0.49 and less (= low ORA) / **group B:** ORA = 0.50 to 1.24 (= medium ORA) / **group C:** ORA = 1.25 and more (= high ORA)

	N	Min	Max	Mean	SD	Median	Q25	Q75	P-Value
Starburst**									
Group A	12	1	2	1,08	0,29	1	1	1,00	0,247
Group C	18	1	1	1,00	0,00	1	1	1,00	
Glare**									
Group A	12	1	4	1,67	0,98	1	1	2,00	0,595
Group C	18	1	4	1,61	0,14	1	1	1,75	
Halo**									
Group A	12	1	1	1,00	0,00	1	1	1,00	NaN
Group C	18	1	4	1,00	0,00	1	1	1,00	
Double vision & ghost images**									
Group A	12	1	4	1,25	0,87	1	1	1,00	0,0247
Group C	18	1	1	1,00	0,00	1	1	1,00	
Dry Eyes**									
Group A	12	1	4	1,33	0,89	1	1	1,00	0,218
Group C	18	1	5	1,78	1,17	1	1	2,00	
Satisfaction with vision***									
Group A	12	1	2	1,17	0,39	1	1	1,00	0,737
Group C	18	1	4	1,22	0,43	1	1	1,00	

**Scale of symptoms: low symptoms (1) to strong symptoms (7)

***Scale of satisfaction: very satisfied (1) to very unsatisfied (5)

Supplementary Data 10: Postoperative side effects of Stage 4Stage 4: Grouped by ORA magnitude, matched for MRC & then subdivided by CA magnitude // **group A:** CA < 0,75D (low CA) / **group B:** CA ≥ 0,75D

	N	Min	Max	Mean	SD	Median	Q25	Q75	P-Value
Starburst**									
Group A	8	1	1	1,00	0,00	1	1	1,00	NaN
Group B	10	1	1	1,00	0,00	1	1	1,00	
Glare**									
Group A	8	1	4	1,88	1,36	1	1	2,50	0,429
Group B	10	1	4	1,40	0,97	1	1	1,75	
Halo**									
Group A	8	1	1	1,00	0,00	1	1	1,00	NaN
Group B	10	1	1	1,00	0,00	1	1	1,00	
Double vision & ghost images**									
Group A	8	1	1	1,00	0,00	1	1	1,00	NaN
Group B	10	1	1	1,00	0,00	1	1	1,00	
Dry Eyes**									
Group A	8	1	4	1,50	1,07	1	1	1,25	0,334
Group B	10	1	4	2,00	1,25	1,5	1	2,00	
Satisfaction with vision***									
Group A	8	1	2	1,12	0,35	1	1	1,00	0,423
Group B	10	1	2	1,30	0,48	1	1	1,00	

**Scale of symptoms: low symptoms (1) to strong symptoms (7)
***Scale of satisfaction: very satisfied (1) to very unsatisfied (5)